Immunotherapy Archives

News and Trends 15 Dec 2016

Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials

Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […]

December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Dec 2016

Swedish Therapy targeting All Solid Tumors enrolls First Patient

Immunicum just received FDA approval to start clinical trials in the US for a therapy that could overcome the challenges of T-cell therapies and target virtually any injectable solid tumor. Immunicum is a biotech from Gothenburg, Sweden, that focuses on immuno-oncology with a different approach from most companies. Instead of T-cells, the company engineers dendritic […]

December 14, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Dec 2016

Video: Chatting with Immunocore about the Potential of Immuno-oncology

At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe’s hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest biotech successes in Europe: the company raised the largest round ever on the continent (€300M!), built a solid technological platform and recruited top talents to manage […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 29 Nov 2016

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […]

November 29, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

News and Trends 18 Nov 2016

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […]

November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

medimmune astrazeneca cancer pd l1 nsclc trial pd l1

News and Trends 28 Oct 2016

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […]

October 28, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials

Swedish Therapy targeting All Solid Tumors enrolls First Patient

How is European Immuno-Oncology fighting Blood Cancer?

Video: Chatting with Immunocore about the Potential of Immuno-oncology

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Cell Therapies: Is Commercialization holding back a Breakthrough?

European Biotech is working hard to Beat back Melanoma

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!